Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.720
-0.020 (-1.15%)
Dec 5, 2025, 4:00 PM EST - Market closed
Lineage Cell Therapeutics Employees
As of December 31, 2024, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees increased by 2 or 2.67% compared to the previous year.
Employees
77
Change (1Y)
2
Growth (1Y)
2.67%
Revenue / Employee
$140,468
Profits / Employee
-$878,662
Market Cap
416.80M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LCTX News
- 22 days ago - Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy - Seeking Alpha
- 4 weeks ago - Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 5 weeks ago - Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 - Business Wire
- 3 months ago - Lineage Cell Therapeutics, Inc. (LCTX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript - Seeking Alpha
- 3 months ago - Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes - Business Wire
- 3 months ago - Lineage Cell Therapeutics to Present at September 2025 Investor Conferences - Business Wire
- 3 months ago - Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss - Business Wire